Cipla Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1388 as of 12 Jun 15:30 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 25.5 on March 2026 . This represents a CAGR of -1.13% over 6 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 98795 crore on March 2026 . This represents a CAGR of 7.02% over 6 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Cipla Ltd for the Mar '26 is ₹ 6689 crore as compare to the Dec '25 revenue of ₹ 7280 crore. This represent the decline of -8.12% The revenue of Divis Laboratories Ltd for the Mar '26 is ₹ 2986 crore as compare to the Dec '25 revenue of ₹ 2692 crore. This represent the growth of 10.92% The ebitda of Cipla Ltd for the Mar '26 is ₹ 1103 crore as compare to the Dec '25 ebitda of ₹ 1185 crore. This represent the decline of -6.95% The ebitda of Divis Laboratories Ltd for the Mar '26 is ₹ 1089 crore as compare to the Dec '25 ebitda of ₹ 904 crore. This represent the growth of 20.46% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 550.11 crore over 8 quarters. This represents a CAGR of -31.61% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 751 crore over 8 quarters. This represents a CAGR of 32.16% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 29.87 % on March 2026 . This represents a CAGR of 10.58% over 6 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Cipla Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Cipla Ltd or Divis Laboratories Ltd?

Market cap of Cipla Ltd is 112,193 Cr while Market cap of Divis Laboratories Ltd is 176,086 Cr

What are the key factors driving the stock performance of Cipla Ltd and Divis Laboratories Ltd?

The stock performance of Cipla Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Divis Laboratories Ltd?

As of June 14, 2026, the Cipla Ltd stock price is INR ₹1388.8. On the other hand, Divis Laboratories Ltd stock price is INR ₹6633.05.

How do dividend payouts of Cipla Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Cipla Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.